Indian companies have established themselves well within the U.S., and the American market is an important source of income for many Indian companies in areas like IT, pharmaceuticals, consulting, and business services. Many top Indian companies cater to a large customer base within the U.S. and earn a substantial amount of money from it.
With technology firms offering digital transformation services and pharmaceutical companies providing medications, such enterprises have been able to develop a strong foothold within the country. This shows how important the US is for the corporate world in India, as well as the extent of globalization of Indian firms. Here are a few Indian companies earning the highest revenue of up to 80.6 percent from the United States
Persistent Systems Limited
With a market capitalization of Rs. 84,868.71 crore, the shares of Persistent Systems Limited closed at Rs. 5,379.95 per equity share, rising nearly 1.97 percent from its previous day’s close price of Rs. 5,276 per equity share.
Persistent Systems Limited is an Indian technology services company that provides its expertise in digital engineering, cloud computing, data and analytics, artificial intelligence, and enterprise modernization. The firm is based in Pune, Maharashtra, and provides its services to various clients from industries like banking, healthcare, life sciences, and technology.
Looking at the company’s recent quarter highlights, Persistent Systems Limited’s revenue has increased from Rs. 3,334 crore in Q1 FY26 to Rs. 4,303 crore in Q1 FY27, which has grown by 29.06 percent. The net profit has also grown by 13.65 percent from Rs. 425 crore in Q1 FY26 to Rs. 483 crore in Q1 FY27.
Persistent Systems Limited has a highly diversified global revenue base, with North America which is mainly constituted by the US, contributing 80.6 percent of total revenue . Europe accounts for 8.7 percent, while India contributes 8.8 percent and the Rest of the World (ROW) contributes 1.9 percent, highlighting its strong presence in international markets.
Lupin Limited
With a market capitalization of Rs. 95,573.60 crore, the shares of Lupin Limited closed at Rs. 2090.00 per equity share, down nearly 0.38 percent from its previous day’s close price of Rs. 2,098.00 per equity share.
Lupin Limited is one of the most successful pharmaceutical companies of India that specializes in the research, production, and distribution of generics, branded formulations, specialty products, and active pharmaceutical ingredients. It has its headquarters located in Mumbai, Maharashtra, and operates in the international markets including the US and India.
Looking at the company’s recent quarter highlights, Lupin Limited’s revenue has increased from Rs. 6,268 crore in Q1 FY26 to Rs. 8,277 crore in Q1 FY27, which has grown by 32.05 percent. The net profit has also grown by 16 percent from Rs. 1,221 crore in Q1 FY26 to Rs. 1,417 crore in Q1 FY27.
Lupin Limited has a diversified sales mix across key global markets. The United States contributes 42 per cent of total revenue, followed by India at 29 per cent. Other Developed Markets account for 14 percent, while Emerging Markets contribute 12 percent. API sales make up the remaining 3 percent, reflecting Lupin’s broad geographical and business exposure.
Aurobindo Pharma Limited
With a market capitalization of Rs. 98,464.42 crore, the shares of Aurobindo Pharma Limited closed at Rs. 1711.30 per equity share, down nearly 0.51 percent from its previous day’s close price of Rs. 1,720.00 per equity share.
Aurobindo Pharma Limited is an Indian pharmaceutical firm that deals in the production and distribution of generic drugs, active drug ingredients, and specialty pharmaceuticals. The firm is headquartered in Hyderabad, Telangana, and has made great strides to penetrate global markets such as the United States and Europe.
Looking at the company’s recent quarter highlights, Aurobindo PharmaLimited’s revenue has increased from Rs. 7,868 crore in Q1 FY26 to Rs. 9,150 crore in Q1 FY27, which has grown by 16.29 percent. The net profit has also grown by 25.20 percent from Rs. 824 crore in Q1 FY26 to Rs. 1,032 crore in Q1 FY27.
Aurobindo Pharma Limited reported revenue of Rs. 9,150 crore in Q1 FY27, with the US market contributing 41.2 percent of consolidated revenue. This translates to approximately Rs. 3,770 crore in US revenue, highlighting the significant contribution of the US market to the company’s overall performance.
Wipro Limited
With a market capitalization of Rs. 1,62,594.61 crore, the shares of Wipro Limited closed at Rs. 164.15 per equity share, rising nearly 0.34 percent from its previous day’s close price of Rs. 163.60 per equity share.
Wipro Limited is one of the largest companies dealing with IT and consulting in India, with its headquarters in Bengaluru, Karnataka. It offers a variety of services such as digital transformation, cloud computing, artificial intelligence, cyber security, data analytics, engineering, and technology consulting to customers around the world.
Looking at the company’s recent quarter highlights, Wipro Limited’s revenue has increased from Rs. 22,135 crore in Q1 FY26 to Rs. 24,479 crore in Q1 FY27, which has grown by 10.59 percent. The net profit has also grown by 0.60 percent from Rs. 3,336 crore in Q1 FY26 to Rs. 3,356 crore in Q1 FY27.
Wipro Limited reported Rs. 24,479 crore revenue in Q1 FY27. The Americas contributed 60.6 percent in total (Americas 1 – 35.2 percent, and Americas 2 – 25.4 percent), amounting to approximately Rs. 14,835 crore. Europe contributed 27.2 percent (Rs. 6,658 crore), while APMEA accounted for 12.2 percent (Rs. 2,986 crore).
Sun Pharmaceutical Industries Limited
With a market capitalization of Rs. 4,44,706.26 crore, the shares of Sun Pharmaceutical Industries Limited closed at Rs. 1853.50 per equity share, rising nearly 0.03 percent from its previous day’s close price of Rs. 1,853.00 per equity share.
Sun Pharmaceutical Industries Limited is one of India’s major pharmaceutical companies, engaged in the development, manufacturing, and marketing of generic medicines, specialty pharmaceuticals, and active pharmaceutical ingredients. Headquartered in Mumbai, Maharashtra, Sun Pharma has a strong global presence and serves patients across numerous international markets.
Looking at the company’s recent quarter highlights, Sun Pharmaceutical Industries Limited’s revenue has increased from Rs. 13,851 crore in Q1 FY26 to Rs. 15,300 crore in Q1 FY27, which has grown by 10.46 percent. The net profit has also grown by 26.52 percent from Rs. 2,293 crore in Q1 FY26 to Rs. 2,901 crore in Q1 FY27.
Sun Pharmaceutical Industries Limited has a diversified revenue base, with India Formulations contributing 33 percent of FY26 sales, followed by US Formulations at 29 percent and Emerging Markets Formulations at 19 percent. Rest of World (RoW) Formulations account for 15 percent, while API & Others contribute 4 percent, based on total FY26 sales of Rs. 582 billion.